BCR-ABL positive chronic myelogenous leukemia
Drug research and approvals for BCR-ABL positive chronic myelogenous leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 82 studies of BCR-ABL positive chronic myelogenous leukemia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 82
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsNCT07905183 · Phase 3 · Enliven Therapeutics · starts Dec 31, 2026
- Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsNCT07789574 · Phase 2 · Thomas Ernst, Prof. Dr. med. · starts Nov 1, 2026
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNCT07758218 · Phase 1 · University of Wisconsin, Madison · starts Nov 1, 2026
- Vididencel in CML-CP Patients With MRDNCT07651878 · Phase 1 · Mendus · starts Apr 14, 2026
- Impact of Targeted Therapy on Cancer-Related Cognitive ImpairmentNCT07638007 · Not reported · University of Rochester NCORP Research Base · starts Nov 21, 2025
- A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive…NCT07549516 · Not reported · Novartis Pharmaceuticals · starts Apr 17, 2026
- Safety and Tolerability of ZE74-0282 in Healthy VolunteersNCT07527221 · Phase 1 · Eilean Therapeutics AU Pty Ltd · starts Apr 16, 2026
- MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With…NCT07362225 · Not reported · MPN Research Foundation · starts Sep 26, 2025
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNCT07354074 · Phase 2 · Novartis Pharmaceuticals · starts Apr 28, 2026
Approved 9
- NilotinibTyrosine-protein kinase ABL inhibitor
- DasatinibTyrosine-protein kinase ABL inhibitor
- ImatinibTyrosine-protein kinase ABL inhibitor
- BosutinibTyrosine-protein kinase ABL inhibitor
- AsciminibTyrosine-protein kinase ABL inhibitor
- PonatinibBcr/Abl fusion protein inhibitor
- BusulfanDNA inhibitor
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- Interferon alfa-2bInterferon alpha/beta receptor agonist
Phase 3 12 of 13
- CytarabineDNA inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Peginterferon alfa-2bInterferon alpha/beta receptor agonist
- OlverembatinibBcr/Abl fusion protein inhibitor
- CyclophosphamideDNA inhibitor
- Fludarabine
- CyclosporineCyclophilin A modulator
- MethotrexateDihydrofolate reductase inhibitor
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- Peginterferon alfa-2aInterferon alpha/beta receptor agonist
- FlumatinibTyrosine-protein kinase ABL inhibitor
- RadotinibBcr/Abl fusion protein inhibitor
Phase 2 12 of 28
- Omacetaxine mepesuccinateProtein synthesis inhibitor
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- TacrolimusFK506-binding protein 1A inhibitor
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- ClofarabineRibonucleoside-diphosphate reductase RR1 inhibitor
- VenetoclaxApoptosis regulator Bcl-2 inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- IdarubicinDNA topoisomerase II alpha inhibitor
- PanobinostatHistone deacetylase inhibitor
- AldesleukinInterleukin-2 receptor agonist
Phase 1 or earlier 12 of 54
- ZileutonArachidonate 5-lipoxygenase inhibitor
- TozasertibSerine/threonine-protein kinase Aurora inhibitor
- AcetaminophenCyclooxygenase inhibitor
- Arsenic trioxideThioredoxin reductase 1 inhibitor
- DaunorubicinDNA topoisomerase II alpha inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- Inotuzumab ozogamicinBlast crisis · CD22 binding agent
- IsotretinoinRetinoic acid receptor agonist
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- MitoxantroneDNA topoisomerase II alpha inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- VorinostatHistone deacetylase 1 inhibitor
How its trials ended
979 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 315 whose ending is known, 37% met their primary endpoint, 3% missed it and 61% stopped early.
- Completed, result not reported39140%
- Ongoing17618%
- Met its primary endpoint11512%
- Stopped: other or unclear10411%
- Status unknown9710%
- Stopped: enrollment or feasibility566%
- Stopped: sponsor or business decision131%
- Missed its primary endpoint81%
- Stopped: lack of efficacy81%
- Stopped: funding71%
- Stopped: safety4<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA